Beta-adducin (ADD2)

Beta-adducin is a membrane cytoskeletal protein encoded by the ADD2 gene, belonging to the adducin family, which also includes alpha- and gamma-adducin[1][3][6]. Beta-adducin is primarily expressed in the brain and hematopoietic tissues and forms heteromeric complexes (primarily α/β or α/γ) crucial for assembling and maintaining the spectrin-actin network beneath the plasma membrane, especially in erythrocytes and at cell-cell contacts in epithelial tissues[1][5][6][7]. In erythrocytes, beta-adducin is essential for membrane stability—its absence leads to osmotically fragile, misshaped red blood cells, similar to hereditary spherocytosis in humans[9]. In the nervous system, beta-adducin is enriched at synapses, where its regulated phosphorylation is required for dendritic spine remodeling, synaptogenesis, and cognitive functions like memory formation[1][5]. Additionally, genetic variants in ADD2 have been associated with hypertension, linking this protein to membrane stability in vascular and renal tissues[1][4]. Beta-adducin is subject to regulation by phosphorylation and calmodulin binding, which affect its interaction with actin, spectrin, and other cytoskeletal proteins[5][6][7]. Summary: Beta-adducin (ADD2) is a critical cytoskeletal assembly factor not classically considered a therapeutic target (like an enzyme or receptor), but it is biologically important for membrane stability, synaptic function, and blood pressure regulation[1][3][5][6][9]. No drugs are currently reported to act directly on beta-adducin.

Other names

Beta-adducinADDBadducin 2erythrocyte adducin subunit betaadducin 2 (beta)